The meeting, chaired by Morten Jurs, recorded attendance of shareholders representing 34.59% of the company's shares. Morten Jurs was elected as chairperson and Tore Grøttum to co-sign the minutes. The agenda and notice were approved unanimously. The annual accounts and directors' report for 2024 were approved, including the allocation of the year's results. Remuneration for the company's auditor was approved as per the annual accounts. New board members were elected: Morten Jurs (Chairperson), Camilla Huse Bondesson, Ove Öhman, Thorvald Steen, Rune Sørum, and Jonathan Kohn, with unanimous approval. Board remuneration was set, with specific amounts for each member, and was unanimously agreed upon. Members of the nomination committee were elected: Bjørn Fuglaas (Chair), Svein Lien, and Kari Stenersen, with remuneration also approved unanimously. The board was authorized to increase the share capital by up to NOK 12,000,000 until the 2027 AGM, and to acquire own shares up to NOK 3,600,000, both with unanimous agreement. The share option program was extended, allowing management and employees to acquire up to 1,580,000 shares, with the board authorized to increase share capital for this purpose by up to NOK 3,223,551, valid until the 2027 AGM. All resolutions were passed unanimously. For more information, contact Ronny Hermansen, CEO.

IBS is a common gastrointestinal disorder affecting 5-10% of the global population, with 70% of patients experiencing altered gut microbiota composition. This condition incurs significant costs, with annual expenses in the U.S. estimated at USD 30 billion. The global IBS diagnostics market is projected to grow from USD 3.3 billion in 2025 to USD 5.4 billion by 2034. A patent, effective until 2040, focuses on analyzing gut microbiota to improve IBS treatment by identifying patients likely to respond to specific therapies. This development enhances the intellectual property portfolio of the company involved and emphasizes the role of microbiota profiling in clinical decisions. Ronny Hermansen, CEO of Genetic Analysis, highlights the importance of this patent in advancing microbiome-based diagnostics to optimize treatment for IBS, affecting around 100 million people in the U.S. and Europe.

DDW offers insights into the gastrointestinal field and networking opportunities. Genetic Analysis representatives, including Kari Furu, Christina Casén, and Zuzanna Gulczynska, will attend to showcase their microbiome testing platform, GA-map®. They will highlight its use for discovering microbiome-based biomarkers and developing precision medicine strategies, specifically their GA-map® IBD Precision Dx product for early Ulcerative Colitis patient stratification. The test helps identify aggressive disease profiles for better treatment planning. Genetic Analysis will also participate in the scientific program, with Kari Furu presenting on gut microbiome innovation and a poster session on microbiome restoration in collaboration with Ferring Pharmaceuticals. Attendance at DDW supports Genetic Analysis's efforts in advancing microbiome-based diagnostics. For more information, contact CEO Ronny Hermansen.

The GA-map® Dysbiosis Test is a diagnostic tool used to analyze gut microbiomes and assess intestinal dysbiosis by comparing a patient's microbiome with a healthy reference group. Although microbiome analysis offers insights into bacterial imbalances, interpreting these complex profiles can be challenging in clinical settings. AInsight aids healthcare professionals by organizing microbiome findings and explaining deviations in bacterial levels using scientific evidence. It employs an AI language model to provide clinically relevant associations for each bacterial marker identified by the GA-map® Dysbiosis Test. This simplification aims to enhance the clinical application of the test and increase demand for GA's reagent kits. AInsight operates within a controlled system, only accessing information from GA’s curated Bacteria Compendium, ensuring that reports align with the scientific basis of the GA-map® Dysbiosis Test. This setup allows for automated, structured interpretation reports for individual microbiome profiles, facilitating scalable report generation and helping laboratories manage higher testing volumes efficiently. CEO Ronny Hermansen expressed satisfaction with the introduction of AInsight, highlighting its role in making microbiome diagnostics more accessible in routine healthcare and supporting the broader use of the GA-map® Dysbiosis Test. The reports are meant to support information interpretation and should be considered within a broader clinical context by qualified professionals. AInsight is a strategic move to expand the clinical use of GA's diagnostic platform. For more information, contact CEO Ronny Hermansen via email.

Ronny Hermansen, CEO of Genetic Analysis, highlighted the company's progress in Q4 2025, emphasizing their long-term growth strategy in commercial expansion and product development. The company is enhancing collaborations to strengthen its GA-map® technology in microbiome diagnostics, aiming to provide reliable testing solutions globally. Sales revenue reached NOK 6.4 million in Q4, marking an all-time high, with a yearly total of NOK 16.7 million. Despite a decline in gross margin from 83% to 68% due to US import duties and currency effects, core product sales grew significantly. EBITDA was negatively impacted by these factors, totaling NOK -2.1 million. Cash flow from operations improved to NOK 2.4 million, and cash reserves increased to NOK 24.0 million by year-end, aided by a customer pre-payment. Key developments include the completion of a biomarker panel in the IBD Precision Dx project and the granting of patents in Canada and the US, enhancing the protection of their diagnostic technology.

Företaget har meddelat att det korrekta datumet för publiceringen av årsbokslutet för 2025 är den 27 februari 2026, enligt den finansiella kalendern i delårsrapporten för första kvartalet 2025. Ett felaktigt datum, den 25 februari 2026, angavs i delårsrapporten för tredje kvartalet 2025. Företaget betonar att inget formellt beslut om att ändra rapporteringsdatumet har fattats. Det korrekta datumet har även publicerats på företagets webbplats och Spotlight Stock Markets företagssida. För mer information kan Ronny Hermansen, VD, kontaktas via e-post.

CEO Ronny Hermansen highlights the importance of high analytical accuracy in molecular diagnostics and mentions that a new patent protects technology designed to reduce false-positive signals, thereby enhancing the reliability of diagnostic tests. This patent, approved by the United States Patent and Trademark Office and expected to be issued in Q1 2026, strengthens the company's position in the U.S. market and supports its long-term strategy. The technology improves the accuracy of DNA-based tests by addressing errors caused by unintended binding of reagents and enzymes, with practical steps to minimize these effects. The patent, which claims priority from January 30, 2015, will remain in force until 2036.

En familj av patent, utvecklade av Genetic Analysis, handlar om avancerade algoritmer för att analysera och karakterisera tarmmikrobiota i relation till hälsosamma populationer. Dessa uppfinningar är inriktade på diagnos, övervakning och karakterisering av sjukdomar och tillstånd kopplade till förändringar i mag-tarmkanalens mikrobiota. Patenten erbjuder metoder för att bedöma mikrobiotans tillstånd och identifiera avvikelser från det normala tillståndet på ett enkelt, tillförlitligt och flexibelt sätt, oavsett vilken teknik som används för att mäta mikroorganismer i ett GI-prov. Det kanadensiska patentkontoret har godkänt patentet, och det förväntas utfärdas formellt under första kvartalet 2026. Patentfamiljen har prioritetsdatum den 27 mars 2015 och kommer att vara giltig till 2036. CEO Ronny Hermansen uttrycker glädje över godkännandet i Kanada, vilket stärker företagets immateriella rättigheter och är ett viktigt steg i deras internationella expansion. För mer information kan Ronny Hermansen kontaktas via e-post.

Genetic Analysis reported consistent progress in Q3 2025, with sales slightly higher than the previous year despite a slower summer period. Operating income for the quarter was NOK 3.2 million, with sales revenue at NOK 2.1 million, marking a 2.9% increase from the previous year. The company faced a net loss of NOK 3.3 million, and EBITDA was stable at NOK -1.8 million. The gross margin decreased to 64% due to US import duties, which negatively impacted results, although lower operating costs provided some relief. Significant events included the launch of the GA-map® MHI GutHealth test in the US and globally, developed with Ferring Pharmaceuticals, targeting antibiotic-induced microbiome imbalances. The company also advanced its IBD Precision Dx project to the validation phase. Total assets stood at NOK 43.8 million, with an equity ratio of 67%. Earnings per share were NOK -0.05. The company attended the ADLM congress in Chicago to showcase its new test, reaching a broad audience.

The IBD Precision Dx project aims to create a microbiome-based diagnostic test to predict the disease course in Ulcerative Colitis (UC) patients, aiding in earlier and more targeted treatment decisions. This project is a collaboration with Akershus University Hospital and the University hospital of Gothenburg, supported by EUR 2 million from the Research Council of Norway. Genetic Analysis (GA) has completed the bacteria biomarker panel design, facilitating the stratification of UC patients by disease severity through stool sample analysis. GA, with extensive IBD research experience since 2013, has developed the GA-map® IBD Precision Dx using its proprietary technology for commercialization on the Luminex® xMAP® platform. The test addresses a clinical need, as no current diagnostic tool predicts UC disease severity, which is crucial for optimizing treatment and improving patient outcomes. The project leaders express optimism about the test's potential to support personalized treatment strategies and reduce healthcare costs, with plans to launch the test in 2026.